

AIH EVENT RESOURCES

The management of AIH has evolved over recent years.

Changes to the definition of remission and the increasing importance of the patient in treatment decisions combined with poor quality of life from the use of steroids have all combined to establish the need for a change to the management of patients with mild to moderate AIH.

The recent AASLD guidelines highlight the importance of optimising the use of budesonide in the management of patients with mild to moderate AIH.

3 out of 4 patients do not have cirrhosis at diagnosis and would be suitable for budesonide as initial treatment in appropriate patients*

*(Definition of mild to moderate AIH Mild to Moderate :AST<400 Normal INR <1.3 No jaundice/normal bilirubin/normal albumin/ No evidence of cirrhosis)

The meeting materials and slide sets attached provide a set of resources to help educate and provide the management of AIH in mild to moderate disease along with practical guidance on prescribing steroids and switching.

1. Czaja AJ. World J Gastroenterol 2010; 16(8): 934-47.
2. Corrigan M et al. Poster presented at The International Liver Congress 2017; Amsterdam, Netherlands, April 2017.
3. Dyson JK et al. Aliment Pharmacol Ther 2018; 48(9): 951-60.
4. Mack CL et al. Hepatology 2020; 72(2): 671-722.
5. Lyn Lee Wong et al Hepatology 2018 vol 68 no 4

